Bicyclic heterocycles as cannabinoid-1 receptor modulators

1. A compound or a pharmaceutically acceptable salt or a stereoisomer thereof according to Formula I

wherein:

A is N;

B is selected from the group consisting of a direct bond, oxygen, sulfur, NR 6 , C(O), C(O)O, OC(O), OC(O)O, C(O)NR 6 , NR 6 C(O), NR 6 C(O)O, S(O), S(O) 2 , S(O)NR 6 , S(O) 2 NR 6 , NR 6 S(O), NR 6 S(O) 2 , and NR 6 C(O)NR 7 ;

R 1 and R 2 are independently selected from the group consisting of aryl substituted with 1 to 5 R 4 and heteroaryl optionally substituted with 1 to 4 R 4 ;

when both R 1 and R 2 are heteroaryl, then either R 1 or R 2 is substituted with at least one R 4 ;

R 3 is selected from the group consisting of hydrogen, halogen, CF 3 , OCHF 2 , OCF 3 , CN, NO 2 , OCH 3 , SCH 3 , OR 5 , SR 5 , NR 5 R 6 , C(O)H, C(O)R 5 , C(O)NR 5 R 6 , NR 6 C(O)R 5 , C(O)OR 5 , OC(O)R 5 , OC(O)OR 5 , S(O)R 5 , S(O) 2 R 5 , S(O)NR 5 R 6 , S(O) 2 NR 5 R 6 , NR 6 S(O)R 5 , NR 6 S(O) 2 R 5 , NR 6 C(O)R 5 , NR 6 C(O)OR 5 , NR 6 S(O) 2 R 5 , NR 6 C(O)NR 7 R 5 , alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl, any of which may be optionally substituted with 1 to 6 R 9 ;

R 4 , at each occurrence, is independently selected from the group consisting of halogen, OH, CF 3 , OCHF 2 , OCF 3 , CN, NO 2 , OCH 3 , SCH 3 , OR 5 , SR 5 , NR 5 R 6 , C(O)H, C(O)R 5 , C(O)NR 5 R 6 , NR 6 C(O)R 5 , C(O)OR 5 , OC(O)R 5 , OC(O)OR 5 , S(O)R 5 , S(O) 2 R 5 , S(O)NR 5 R 6 , S(O) 2 NR 5 R 6 , NR 6 S(O)R 5 , NR 6 S(O) 2 R 5 , NR 6 C(O)R 5 , NR 6 C(O)OR 5 , NR 6 S(O) 2 R 5 , NR 6 C(O)NR 5 R 7 , alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, any of which may be optionally substituted with 1 to 6 R 9 ;

R 5 is selected from the group consisting of C 1-4 alkyl optionally substituted with 1 to 3 R 9 , C 2-4 alkenyl optionally substituted with 1 to 2 R 9 , C 2-4 alkynyl optionally substituted with 1 to 2 R 9 , C 3-10 cycloalkyl optionally substituted with 1 to 6 R 10 , C 3-10 heterocyclyl optionally substituted with 1 to 6 R 10 , aryl optionally substituted with 1 to 5 R 11 and heteroaryl optionally substituted with 1 to 3 R 10 ;

R 6 and R 7 are independently is selected from the group consisting of hydrogen, C 1-4 alkyl optionally substituted with 1 to 3 R 9 , C 2-4 alkenyl optionally substituted with 1 to 2 R 9 , C 2-4 alkynyl optionally substituted with 1 to 2 R 9 , C 3-6 cycloalkyl optionally substituted with 1 to 3 R 10 , and C 3-6 heterocyclyl optionally substituted with 1 to 3 R 10 ;

alternatively, R 5 and R 6 join to form a 3 to 7-membered ring optionally substituted with oxygen or NR 12 ;

alternatively, R 5 and R 6 when attached to N may be combined to form a 5 to 10-membered bicyclic heterocyclic ring system containing from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said bicyclic heterocyclic ring system is unsaturated or partially saturated, wherein said bicyclic heterocyclic ring system is optionally substituted with 1 to 3 R 13 ;

alternatively, R 6 and R 7 join to form a 5 to 7-membered ring optionally substituted with oxygen or NR 12 ;

alternatively, R 6 and R 7 when attached to N may be combined to form a 9- or 10-membered bicyclic heterocyclic ring system containing from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said bicyclic heterocyclic ring system is unsaturated or partially saturated, wherein said bicyclic heterocyclic ring system is optionally substituted with 1 to 3 R 13 ;

R 8 is selected from the group consisting of alkyl optionally substituted with 1 to 6 R 9 , alkenyl optionally substituted with 1 to 6 R 9 , alkynyl optionally substituted with 1 to 6 R 9 , cycloalkyl optionally substituted with 1 to 6 R 10 , heterocyclyl optionally substituted with 1 to 6 R 10 , aryl optionally substituted with 1 to 5 R 4 , heteroaryl optionally substituted with 1 to 3 R 4 ;

R 9 , at each occurrence, is independently selected from the group consisting of halogen, OH, CF 3 , OCHF 2 , OCF 3 , CN, NO 2 , OCH 3 , SCH 3 , OR 12 , SR 12 , NR 12 R 12a , C(O)H, C(O)R 12 , C(O)NR 12 R 12a , NR 12 C(O)R 12a , C(O)OR 12 , OC(O)R 12 , OC(O)OR 12 , S(O)R 12 , S(O) 2 R 12 , S(O)NR 12 R 12a , S(O) 2 NR 12 R 12a , NR 12 S(O)R 12a , NR 12 S(O) 2 R 12a , NR 12 C(O)R 12a , NR 12 C(O)OR 12a , NR 12 S(O) 2 R 12a , C 1-3 haloalkyl, C 1-4 alkoxy, C 3-6 cycloalkyl optionally substituted with 1 to 3 R 10 , C 3-10 heterocyclyl optionally substituted with 1 to 3 R 10 , aryl optionally substituted with 1 to 5 R 11 and heteroaryl optionally substituted with 1 to 3 R 10 ;

R 10 , at each occurrence, is independently selected from the group consisting of ═O, halogen, OH, CF 3 , OCHF 2 , OCF 3 , CN, NO 2 , OCH 3 , SCH 3 , OR 12 , SR 12 , NR 12 R 12a , C(O)H, C(O)R 12 , C(O)NR 12 R 12a , NR 12 C(O)R 12a , C(O)OR 12 , OC(O)R 12 , OC(O)OR 12 ,S(O)R 12 ,S(O) 2 R 12 , S(O)NR 12 R 12a ,S(O) 2 NR 12 R 12a , NR 12 S(O)R 12a , NR 12 S(O) 2 R 12a , NR 12 C(O)R 12a , NR 12 C(O)OR 12a , NR 12 S(O) 2 R 12a , C 1-4 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkoxy and C 1-4 haloalkyl;

R 11 , at each occurrence, is independently selected from the group consisting of halogen, OH, CF 3 , OCHF 2 , OCF 3 , CN, NO 2 , OCH 3 , SCH 3 , C 1-4 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkoxy and C 1-4 haloalkyl;

R 12 and R 12a , at each occurrence, are independently selected from the group consisting of H and C 1-4 alkyl;

R 13 , at each occurrence, is independently selected from the group consisting of H, OH, halogen, CN, NO 2 , CF 3 , C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl and C 1-3 alkoxy.

2. The compound according to claim 1 , wherein R 3 is selected from the group consisting of hydrogen, halogen, CF 3 , OCHF 2 , OCF 3 , CN, OCH 3 , SCH 3 , C 1-4 alkyl.

3. The compound according to claim 1 , wherein B is selected from the group consisting of a direct bond, oxygen, sulfur, NR 6 , C(O), C(O)NR 6 .

4. The compound according to claim 1 , wherein R 8 is selected from the group consisting of C 1-6 alkyl optionally substituted with 1 to 4 R 9 , C 2-6 alkenyl optionally substituted with 1 to 4 R 9 , C 2-6 alkynyl optionally substituted with 1 to 4 R 9 , C 3-8 cycloalkyl optionally substituted with 1 to 4 R 10 ; 3-6 membered heterocyclyl optionally substituted with 1 to 3 R 10 , aryl optionally substituted with 1 to 3 R 4 , 5-10 membered heteroaryl optionally substituted with 1 to 3 R 4 .

5. The compound according to claim 1 , wherein

R 4 , at each occurrence, is independently selected from the group consisting of halogen OH, CF 3 , OCHF 2 , OCF 3 , CN, NO 2 , OCH 3 , SCH 3 , OR 5 , SR 5 , NR 5 R 6 , S(O)R 5 , S(O) 2 R 5 , S(O) 2 NR 5 R 6 , C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, any of which may be optionally substituted with 1 to 6 R 9 ;

R 5 and R 6 are independently selected from the group consisting of methyl, ethyl, n-propyl, i-propyl and cyclopropyl;

alternatively, R 5 and R 6 join to form a 3-6-membered ring optionally substituted with oxygen or NR 12 ;

R 9 , at each occurrence, is independently selected from the group consisting of halogen, OH, CF 3 , OCHF 2 , OCF 3 , CN, OCH 3 and N(CH 3 ) 2 ;

R 12 and R 12a , at each occurrence, are independently selected from the group consisting of H ,methyl and ethyl.

6. The compound according to claim 1 , wherein

R 8 is selected from the group consisting of C 1-4 alkyl optionally substituted with 1 to 4 R 9 , C 3-8 cycloalkyl optionally substituted with 1 to 4 R 10 ; 3-6 membered heterocyclyl substituted with 0 to 3 R 10 , aryl optionally substituted with 1 to 3 R 4 , 5-10 membered heteroaryl optionally substituted with 1 to 3 R 4 ;

R 4 , at each occurrence, is independently selected from the group consisting of halogen OH, CF 3 , OCHF 2 , OCF 3 , CN, NO 2 , OCH 3 , SCH 3 , N(CH 3 ) 2 , methyl, ethyl, n-propyl, i-propyl and cyclopropyl;

R 10 , at each occurrence, is independently selected from the group consisting of ═O, halogen, OH, CF 3 , OCHF 2 , OCF 3 , CN, NO 2 , OCH 3 , SCH 3 , methyl, ethyl, n-propyl, i-propyl and cyclopropyl, NR 12 R 12a , C(O)NR 12 R 12a , C(O)OR 12 .

7. The compound according to claim 1 , wherein R 3 is selected from the group consisting of hydrogen and methyl.

8. The compound according to claim 1 , wherein R 1 is selected from the group consisting of 2-halo-phenyl, 2-(C 1-3 )alkyl-phenyl, 2-(C 1-3 )alkoxy-phenyl, 2-CF 3 -phenyl, 2-CN-phenyl, 2-halo-4-pyridyl, 2-(C 1-3 )alkyl-4-pyridyl, 2-(C 1-3 )alkoxy-4-pyridyl, 2-CF 3 -4-pyridyl, 2-CN-4-pyridyl, 2-halo-4-halophenyl, 2-(C 1-3 )alkyl-4-halo-phenyl, 2-(C 1-3 )alkoxy-4-halo-phenyl, 2-CF 3 -4-halo-phenyl, 2-CN-4-halo-phenyl, 2-halo-4-(C 1-3 )alkyl-phenyl, 2-(C 1-3 )alkyl-4-(C 1-3 )alkyl-phenyl, 2-(C 1-3 )alkoxy-4-(C 1-3 )alkyl-phenyl, 2-CF 3 -4-(C 1-3 )alkyl-phenyl, 2-CN-4-(C 1-3 )alkyl-phenyl, 2-halo-4-(C 1-3 )alkyl-phenyl, 2-(C 1-3 )alkyl-4-(C 1-3 )alkoxy-phenyl, 2-(C 1-3 )alkoxy-4-(C 1-3 )alkoxy-phenyl, 2-CF 3 -4-(C 1-3 )alkoxy-phenyl, 2-CN-4-(C 1-3 )alkoxy-phenyl, 2halo-4-CF 3 -phenyl, 2-(C 1-3 )alkyl-4-CF 3 -phenyl, 2-(C 1-3 )alkoxy-4-CF 3 -phenyl, 2-halo-4-CN-phenyl, 2-(C 1-3 )alkyl-4-CN-phenyl and 2-(C 1-3 )alkoxy-4-CN-phenyl.

9. A compound or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein the compounds are selected from the group consisting of:

10. The compounds according to claim 9 , wherein the compounds are selected from the group consisting of:

11. A pharmaceutical composition, comprising: at least one compound according to claim 1 ; and at least one pharmaceutically acceptable carrier or diluent.

12. The pharmaceutical composition according to claim 11 further comprising: at least one additional therapeutic agent selected from the group consisting of anti-obesity agents, appetite suppressants, anti-diabetic agents, anti-hyperlipidemia agents, hypolipidemic agents, hypocholesterolemic agents, lipid-modulating agents, cholesterol-lowering agents, lipid-lowering agents, HDL-raising agent and anti-hypertensive agents.

13. The pharmaceutical combination according to claim 12 wherein the other therapeutic agent may be administered prior to, simultaneously with, or following the administration of said at least one compound.

14. A method for treating obesity, comprising: administering a therapeutically effective amount of at least one compound according to claim 1 to a patient in need.

15. A method for smoking cessation, comprising: administering a therapeutically effective amount of at least one compound according to claim 1 to a patient in need.